Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
41.92
+0.08 (0.19%)
At close: Oct 30, 2026, 4:00 PM EDT
41.92
0.00 (0.00%)
After-hours: Oct 30, 2026, 4:18 PM EDT
Supernus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Supernus Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $60.5. The average 1-year stock price forecast is 44.32% higher than the current stock price, while the lowest is $55 (+31.20%) and the highest is $67 (+59.83%).
Price Target: $60.5 (+44.32%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Supernus Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel Nicolaus | Stifel Nicolaus | Hold Maintains $55 | Hold | Maintains | $55 | +31.20% | Oct 30, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Oct 30, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $65 | Buy | Maintains | $65 | +55.06% | Oct 21, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $66 | Buy | Reiterates | $66 | +57.44% | Jul 27, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $65 | Buy | Maintains | $65 | +55.06% | Jul 10, 2026 |
Financial Forecast
Revenue This Year
884.42M
from 718.95M
Increased by 23.01%
Revenue Next Year
1.35B
from 884.42M
Increased by 53.17%
EPS This Year
2.39
from 2.40
Decreased by -0.43%
EPS Next Year
4.28
from 2.39
Increased by 79.45%
EPS and Forward PE are based on non-GAAP adjusted numbers.